Grifols to invest $360 million to expand capacities for plasma-derived therapies

Spanish drugmaker Grifols (GRF: MC) says its board of directors has approved a plan for new industrial investments for the Bioscience division for the period 2016-2021, with the goal of expanding the manufacturing capacity to cover the expected growing demand of plasma-derived products for the upcoming years.

Grifols is principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, with direct commercial presence in 30 countries and sales in over 100. The total amount approved is $360 million. The investments will increase the plasma fractionation capacity and purification of the several proteins.

The breakdown of the different projects is as follows:
1) Construction of a new plasma fractionation plant at the industrial complex at Clayton (North Carolina, USA), with a fractionation capacity of 6 million liters per year. The construction will begin the first quarter of 2017 and is scheduled to start production in early 2022.